The cannabis industry is expanding more rapidly than ever before. Hot on its heels is the emerging psychedelics industry. What comes next? Our podcast brings listeners entertaining and insightful discussions with leaders in science, medicine, and health along with their pioneering business counterparts to discuss research and current events.
You Can't 2C Me
The group is joined by the big minds from Psilera Bioscience, Jackie von Salm, PhD and Chris Witowski, PhD, to discuss everything from species of magic mushrooms, to the formation of a regulator’s cannabis association, to India’s Cannabis-Mania that is gripping Bollywood. Our science discussions focus on new psychoactive substances, and the pharmacology within the breadth of variety of the 2C class of compounds. The show ends with a rousing round of “Where’s Vaillencourt?” A 20 questions style game about cannabis GMP compliance and its geography. We’d also like to thank The GMP collective (https://www.gmpcollective.com) for sponsoring this episode.
DMT Release and Ketamine Administration
The group is joined by Joceyln Sheltraw, a social justice and cannabis enthusiast, and the Director of Regional Strategy and New Market Expansion for Headset. The show begins with a discussion on the role of the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act and Good Manufacturing Practices (GMPs) in cannabis business sustainability during the Biden administration followed by discussion of the release of DMT during orgasms. The group also examines balancing the introduction of commercial psychoactive substances in society with the socioeconomic burden of addiction; what impact will psychedelics have on addiction in society. The final news story looks at why administration forms matter for ketamine. The Rapid Fire Science segment reviews a clinical study on ketamine in multiple sclerosis and the paradoxical effects of LSD. Special thank you to Jason Soroosh for helping with this episode.
Clash of the Psychedelics
The group discusses the dichotomy between patenting psychedelics compounds and promoting free and open research, the complexities of South American cannabis in Europe, and the 12,000 year old relationship between humans and psychedelics. Rapid fire science looks at the side by side comparison of two hallucinogenic substances and how well various cannabinoids permeate the skin. To conclude the group plays the 20 questions style game, “Guess the Psychedelics or Cannabis Research Institute”.
Clinical Candy Flipping and Hallucinogenic Beer
The group discusses hallucinogenic beer with a side of clinical candy flipping and other concepts like use of psychedelic experiences to replace prison sentences and how MDMA may act as a glue for marriages and relationships. Rapid fire science examines the promiscuity of psychedelics and the potential applications of CBD analogs. To end, the group plays the 20 questions style game, “Where’s Vaillencourt?”.
Ketamine Infusions and the Paradigm of Bad Trips
The group discusses resetting the brain, psychedelics terminology, ketamine infusions, research on the therapeutic usefulness of bad trips, and updates in the field of cannabis product safety. Special guest Kim Napoli, JD, joins HLI to bring valuable insights to the table. The show ends with a 20 questions style game, Guess the Cannabinoid.
Naturalistic Psychedelics, Delta-8 THC, and You
TNews articles focusing on DEA intimidation related to delta-8 THC, engineering yeast to make psychedelics, and psychedelics use and depression. Scientific publications on the impact of naturalistic psychedelics on drug use and consumer understanding of cannabis labels. The show ends with a game that tests your knowledge of hemp in early warfare.
Customer ReviewsSee All
I really enjoyed your most recent episode regarding the untapped potential within DMT and Ketamine. Your guest Jocelyn was well informed, and I appreciated her perspectives on the topics that you guys covered. Likely very few people out there have the data-insight within the cannabis industry that she does, and it seems even fewer out there are having discussions on how to use that privilege for a good cause. It’s great to finally hear conversations that may contribute to actually moving the needle when it comes to battling genetic defects, the opiate epidemic and other long-standing human/ego conditions around stigmatized topics like psychedelics as a medicine.